Comparison of AI-based Smartphone-derived Gait Parameters With the Gold Standard

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorTechnical University of Munich

About this trial

This monocentric prospective cohort study evaluates the technical agreement between artificial intelligence (AI)-based smartphone-derived gait parameters and an optical motion-capture system as the current technical gold standard for gait analysis. Wearables and smartphone-based inertial measurement units (IMUs) offer a scalable and low-threshold approach to assessing human gait mechanics outside specialized gait laboratories. However, before such approaches can be used reliably in clinical research or future clinical pathways, their technical validity and agreement with established reference systems need to be systematically quantified under controlled conditions.

The study will include 40 healthy adult volunteers without acute or chronic disorders of the lower extremities. Participants will be recruited among employees and students of the TUM School of Medicine and Health. After written informed consent, each participant will undergo standardized gait testing at the TUM Campus in the Olympiapark. During testing, participants will carry an iPhone and an Android smartphone in their trouser pockets while simultaneously being assessed with a Vicon optical motion-capture system. The walking test will consist of repeated two-minute walking trials. First, participants will walk wearing their own trousers. Subsequently, the measurements will be repeated while wearing standardized trousers with defined pocket positions at thigh level. All device and Vicon data will be recorded in parallel.

The primary objective is to evaluate the level of agreement between AI-based smartphone-derived gait parameters and Vicon-based gait analysis. Primary outcome measures include the intraclass correlation coefficient (ICC), Bland-Altman limits of agreement, mean absolute error (MAE), and root mean square error (RMSE) for key spatiotemporal and kinematic gait parameters. These parameters include gait speed, step length, cadence, step time, double support time, gait asymmetry, and lower-limb kinematic angle parameters, particularly knee range of motion. Secondary objectives include comparison between Android and iOS devices, assessment of test-retest reliability, evaluation of the influence of trouser type, and analysis of potential systematic bias.

The study is exploratory and non-invasive. It does not provide direct individual benefit to participants, but it is expected to generate relevant scientific and technical evidence regarding the accuracy, reproducibility, and limitations of smartphone-based gait analysis. The risks for participants are minimal and limited to ordinary walking-related discomfort, mild fatigue, a very low risk of stumbling, and rare minor skin irritation from motion-capture markers. No vulnerable groups will be included. Data will be anonymized and processed in accordance with the General Data Protection Regulation.

Eligibility criteria

Qualifiers

Adults aged 18 years or older. No known acute or chronic disorder or injury of the lower extremities. Ability to walk independently. Sufficient physical capacity to complete a standardized walking test. Ability to understand the study information and provide written informed consent. German-, English-, or Spanish-speaking.

Disqualifiers

Acute injury or disease of the lower extremity. Chronic injury or disease of the lower extremity. Inability to walk independently. Relevant motor impairment or other major limitation affecting safe gait testing. Lack of capacity to provide informed consent. Inability to understand German, English, or Spanish. Insufficient physical capacity to perform the walking test. Any condition that, in the opinion of the study team, would impair participant safety or the validity of the gait measurements.

Trial design

Treatments tested in this trial

  • Gait analysis via vicon- and app-system

Treatment groups

40 Participants
are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators